It has pitched for the introduction of OTC(Over-The-Counter) non-capital-raising DRs which would allow for the conversion of Indian shares into depository receipts without the company raising any capital.
The creation of such OTC instruments would allow global institutions who may be more comfortable with local instruments to take exposure to Indian companies, suggests the firm.
Also Read
“In permitting OTC non-capital-raising DRs, India would join 67 other countries that provide investors with access in this way, including Brazil, South Korea, South Africa and Turkey,” it said.
BNY Mellon officials believe this could potentially bring in billions of dollars of additional liquidity to the Indian markets.
“Not only do they broaden the range of investors who participate in capital markets, adding a DR programme can also enhance the liquidity of an issuer’s securities and result in a higher valuation,” said their press statement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
